Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Aquinox Pharmaceuticals (AQXP) Competitors

Aquinox Pharmaceuticals logo

AQXP vs. CALT, ZYME, CMRX, CDMO, SBTX, MENS, MBX, RVNC, CKPT, and AVTE

Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Jyong Biotech (MENS), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and Aerovate Therapeutics (AVTE).

Aquinox Pharmaceuticals vs. Its Competitors

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, indicating that its stock price is 837% less volatile than the S&P 500.

Aquinox Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Aquinox Pharmaceuticals N/A -30.13%-28.08%

Aquinox Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62
Aquinox Pharmaceuticals$25M20.02-$31.58MN/AN/A

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Aquinox Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Aquinox Pharmaceuticals Neutral

Summary

Aquinox Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 6 of the 9 factors compared between the two stocks.

Get Aquinox Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AQXP vs. The Competition

MetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$500.46M$799.38M$5.57B$9.02B
Dividend YieldN/A4.84%5.25%4.03%
P/E RatioN/A1.3027.1820.14
Price / Sales20.02227.16417.49184.08
Price / CashN/A23.4437.0657.97
Price / Book6.886.178.085.60
Net Income-$31.58M-$27.58M$3.16B$248.50M

Aquinox Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AQXP
Aquinox Pharmaceuticals
N/A$21.26
+4.8%
N/A-47.0%$500.46M$25M0.008
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
2.1372 of 5 stars
$12.50
-0.4%
$21.00
+68.1%
+45.1%$869.16M$93.38M-8.33460
CMRX
Chimerix
0.6386 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.8989 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+64.8%$799.18M$139.91M-5.23320High Trading Volume
SBTX
Silverback Therapeutics
N/A$18.20
+0.7%
N/A+73.7%$656.26MN/A-7.5283Gap Up
High Trading Volume
MENS
Jyong Biotech
N/A$8.41
-1.1%
N/AN/A$639.41MN/A0.0031Gap Down
MBX
MBX Biosciences
2.55 of 5 stars
$11.64
+2.0%
$37.50
+222.2%
N/A$389.06MN/A0.0036Positive News
RVNC
Revance Therapeutics
2.7757 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500
CKPT
Checkpoint Therapeutics
0.5333 of 5 stars
$4.26
flat
$4.33
+1.7%
N/A$370.71M$41K-2.3210
AVTE
Aerovate Therapeutics
N/A$9.99
+8.7%
N/A-82.2%$289.56MN/A-3.3420Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:AQXP) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners